
Vector BioMed is a U.S.-based public benefit corporation and CDMO specializing in lentiviral vector design and manufacturing for cell and gene therapies. Launched following $15M in funding, the company provides essential lentiviral vector capabilities using their proprietary LENTIVERSE platform. They produce high-titer (>10^9 TU/mL) lentiviral vectors using a serum-free, chemically-defined process. Key differentiators include algorithm-optimized vector design, rapid turnaround (months from onboarding to GMP batch release), modular pre-validated systems to reduce costs and avoid royalty-based constraints, and a focus on making advanced therapies accessible in lower-resource settings. They partner with CIRM (California Institute for Regenerative Medicine) on lentiviral vector manufacture.
lentiviral vector design and GMP manufacturing, LENTIVERSE platform, VectorCraft custom lentivirus development, LaunchSuite CAR-T manufacturing solution, anti-CD19 and anti-BCMA CAR-T vectors, third-generation lentiviral vectors, serum-free chemically defined suspension process, column chromatography purification, high-titer lentiviral vectors (>10^9 TU/mL), algorithm-optimized vector design, preclinical and research-grade vector production, IND-ready vectors, clinical and commercial CGMP vector manufacturing, autologous and allogeneic CAR-T, TCR-T, in vivo gene therapy, decentralized and point-of-care CAR-T manufacturing support, modular cleanroom CAR-T facility support, custom assay development, process characterization and validation, regulatory strategy and BLA preparation, royalty-free vector supply, cell and gene therapy CDMO
1 site worldwide
Directory pages this company appears in, each with the full list of matching manufacturers.